Introduction
============

Progressive deterioration in symptoms and an accelerated decline in lung function are features of the natural history of disease in a proportion of patients with asthma \[[@B1]\]. Identifying factors associated with this decline would be an important step in the development of strategies aimed at preventing long-term deterioration, compared with current recommendations that principally address short-term symptom control \[[@B2]\].

Among various factors associated with the decline over time, the clearest evidence to date has linked cigarette smoking to a loss of lung function \[[@B3],[@B4]\]. Although patients with bronchial hyperresponsiveness (BHR) are less likely to develop irreversible airflow obstruction, the presence of BHR has been associated with an accelerated decline in lung function \[[@B5],[@B6]\]. There is no clear link between atopic sensitization and decline in lung function in asthma. However, the absolute level of specific IgE has been related to the development of wheezing in children and a number of positive skin tests to increasing BHR in adults \[[@B7],[@B8]\].

The ASMAL (*AS*sessment of *M*anchester *A*sthmatics *L*ongitudinally) cohort was set up to investigate factors associated with asthma control and lung function \[[@B9]-[@B11]\]. Baseline cross-sectional data suggested that, for sensitized individuals, domestic exposure to high levels of sensitizing allergens is associated with poorer lung function \[[@B11]\]. Surprisingly, even among nonsensitized persons with asthma, high levels of exposure to dust mite or dog allergen were associated with increased BHR \[[@B10]\]. On the basis of these findings, we hypothesized that allergen sensitization and high allergen exposure would be associated with a decline in lung function and increased BHR and airway inflammation over time. Thus, within the ASMAL cohort, we aimed to investigate the effects of sensitization and domestic exposure to common inhalant allergens (dust mite, cat, and dog) on longitudinal changes in lung function and BHR over a 4-year period.

Methods
=======

Participants
------------

We recruited subjects with physician-diagnosed asthma (asthma symptoms in the previous 12 months, treatment with a minimum of a short-acting bronchodilator, and no exacerbations for 4 weeks before recruitment) as previously described \[[@B10],[@B11]\]. The study was approved by the local research ethics committee; subjects provided written informed consent.

Participants attended 2 visits 4 years apart. Previsit medication was withheld as follows: short-acting bronchodilators, 6 hours; long-acting bronchodilators, theophyllines, and leukotriene receptor antagonists, 12 hours; antihistamines, 48 hours.

Procedures
----------

### Exhaled Nitric Oxide

Exhaled nitric oxide (eNO) was measured using a chemiluminescence analyzer (LR2000; Logan Research, Rochester, UK) according to published guidelines \[[@B12]\]. Subjects exhaled from inspiratory capacity to residual volume at a controlled rate (6 L/min) into a wide-bore minimal-resistance Teflon tube. Response time (10%-90%) was \< 0.6 seconds and the sampling rate was 250 L/min; the final value was recorded as the mean of 2 maneuvers.

### Spirometry

Spirometry was performed according to ATS guidelines \[[@B13]\] (Microlab 3000; MicroMedical, Rochester, UK).

### Bronchial Challenge

Bronchial challenge was performed at baseline using either methacholine or histamine. Supply problems precluded the use of the same challenge in all subjects, but previous studies have demonstrated dose equivalence;\[[@B14],[@B15]\] analysis of our data found no evidence of differences between the challenges and no bias in terms of outcomes \[[@B10],[@B11]\]. At the follow-up visit, all subjects had histamine challenge. For either challenge, a modified Yan technique was used \[[@B16]\] \[Koko DigiDoser dosimeter (PDS Research, Louisville, Colo) and \"646\" nebulizer pots (DeVilbiss, Somerset, Pa)\]. Baseline FEV~1~(FEV~1~, forced expiratory volume in 1 second) measurement (best of 3) was performed 1 minute after inhalation of isotonic saline, then cumulative doubling doses of the challenge solution were administered, and FEV~1~was measured 1 minute after each dose. When the FEV~1~had fallen by 20% or more, the challenge was terminated and PD~20~calculated by linear interpolation. Where the FEV~1~did not fall by 20% despite the maximum dose of challenge solution, aPD~20~of 12 mg was assigned (1 doubling dose above the maximum given).

### Sensitization

Sensitization was ascertained by skin prick testing (mite, cat, and dog; Bayer, Elkhart, Ind), and sensitization is defined as a mean wheal diameter of at least 3 mm greater than the negative control.

### Allergen Exposure

Allergen exposure was assessed in dust samples collected from homes by vacuuming a 1-m^2^area of living room carpet and mattress for 2 minutes. Mite, cat, and dog allergen levels were measured using monoclonal antibody-based enzyme-linked immunosorbent assays \[[@B17]-[@B19]\].

Statistical Analysis
--------------------

Statistical analysis was performed using SPSS 12.0 for Windows. The primary end point was change in lung function (FEV~1~and BHR) over time in relation to sensitization status and allergen exposure; 250-mL change in FEV~1~and 1 doubling dose change in PD~20~were considered relevant. On the basis of the data at the baseline visit, a sample size of 200 provided 80% power to detect a 250-mL change in FEV~1~and a sample size of 106 to detect a 1 doubling dose change in PD~20~(*α*error = 0.05). Allergen levels, eNO, and PD~20~were normalized using log-transformation. Between-group differences for nominal variables were investigated using the *χ*^2^test. Lung function variables at 2 visits were compared using the paired *t*test, both overall and for subgroups. Change in lung function over time was calculated and between-group comparisons were made initially by independent *t*tests. Further comparisons were performed using analysis of variance (ANOVA), with possible confounders included in the multivariate model (*P*\< 0.5). ANOVA was employed to investigate possible interaction between exposure and sensitization.

Results
=======

Participants
------------

Two hundred of the original cohort of 399 persons with asthma attended the follow-up visit, at mean 47 months (range of 25-68 months) after the baseline assessment. Subjects attending for follow-up tended to be older (44 vs 35 years old, *P*= 0.001) with a longer duration of asthma (23 vs 17 years, *P*= 0.001), were more likely treated with inhaled corticosteroids (72% vs 58%, *P*= 0.005), and had worse lung function (FEV~1~= 2.50 L vs 3.05 L, *P*\< 0.001) compared with those who did not attend (Table [1](#T1){ref-type="table"}).

###### 

Characteristics of Subgroups Included in the Analysis\*

                        Attended Both Visits   Allergen Samples Collected   Bronchial Challenge at Both Visits                         
  --------------------- ---------------------- ---------------------------- ------------------------------------ ---------- ---------- ----------
  Age (years)           44                     35†                          45                                   41         41         50†
                                               (n = 195)                                                                               
  Sex (% males)         40%                    44%                          39%                                  43%        31%        48%†
  Years with asthma     23                     17†                          23                                   23         20         25†
                        (n = 179)              (n = 132)                    (n = 150)                            (n = 31)   (n = 72)   (n = 78)
  \% on ICS treatment   72%                    58%†                         73%                                  66%        60%        86%†
                        (n = 199)                                                                                (n = 34)              
  ICS dose (*μ*g)       967                    1034                         948                                  1064       830        1042
                        (n = 137)              (n = 101)                    (n = 115)                            (n = 22)   (n = 51)   (n = 64)
  Smoking status (%)                                                                                                                   
   Never                61%                    61%                          59%                                  71%        65%        52%
   Ex                   28%                    23%                          30%                                  17%        27%        33%
   Current              12%                    16%                          12%                                  11%        8%         15%
  Spirometry                                                                                                                           
   FEV~1~(l)            2.50                   3.05†                        2.51                                 2.49       2.87       2.11†
                        (n = 197)              (n = 199)                    (n = 164)                            (n = 33)              (n = 78)
   FVC (l)              3.48                   3.80†                        3.48                                 3.46       3.73       3.27†
                        (n = 166)              (n = 110)                    (n = 137)                            (n = 29)   (n = 63)   (n = 74)
   Reversibility (%)    14%                    13%                          14%                                  14%        8%         18%†
                        (n = 124)              (n = 73)                     (n = 106)                            (n = 18)   (n = 40)   (n = 66)
  PD~20~GM (*μ*g)       0.412                  0.538                        0.422                                0.398      0.394      0.590
                        (n = 118)              (n = 146)                    (n = 103)                            (n = 15)              (n = 17)
  eNO GM (ppb)          11.09                  9.76                         11.04                                11.41      10.77      11.35
                        (n = 173)              (n = 160)                    (n = 149)                            (n = 24)   (n = 80)   (n = 69)
  Atopy (%)             84%                    83%                          82%                                  94%        85%        80%
                        (n = 195)              (n = 195)                    (n = 164)                            (n = 31)   (n = 85)   (n = 79)

\*Where data not available for all subjects in group, the number included in the analysis is shown in parentheses.

†*P*\< 0.05 \"no\" vs \"yes\".

ICS, inhaled corticosteroids.

Of 200 subjects with a longitudinal data collection, 165 had domestic allergen levels determined at visit 1; there were no differences in any of the measurements between subjects with or without allergen exposure assessment. Of these 165, 103 had a bronchial challenge at visit 1 (reasons for not being tested: 31/62 had FEV~1~\< 60%; the remaining subjects declined the test) and 110 at visit 2 (22/55 had FEV~1~\< 60%; the rest declined the test). The 86 subjects who had bronchial challenge at both visits were less often treated with inhaled corticosteroids (60% vs 86%, *P*\< 0.001), had better lung function (FEV~1~= 2.87 L vs 2.11 L, *P*\< 0.001; FVC = 3.73 L vs 3.27 L, *P*\< 0.001; FVC, forced vital capacity), and were less likely to be male (31% vs 48%, *P*= 0.04). Characteristics of the study population are presented in Table [2](#T2){ref-type="table"}.

###### 

Baseline Characteristics of Participants With Allergen Samples Collected

                                         n                            
  -------------------------------------- ----- ---------------------- -----
  Age (years)                            165   Mean 45                
                                               Range 10 to 67         
  Sex                                    165   39% male               
  Years with asthma                      150   Mean 23                
                                               Range 1 to 59          
  Age diagnosed with asthma (years)      150   Mean 23                
                                               Range 0 to 58          
  ICS treatment                          165   73%                    
  ICS dose (BDP dose equivalent, *μ*g)   115   Mean 948               
                                               Median 800             
                                               Range 100 to 4000      
  Smokers                                165   Never                  59%
                                               Ex                     30%
                                               Current                12%
  Lung function                                                       
   FEV~1~(l)                             164   Mean 2.51              
                                               Range 0.71 to 4.91     
   FVC (l)                               137   Mean 3.48              
                                               Range 1.41 to 7.13     
  PD~20~(mg)                             103   GM 0.422               
                                               95% CI 0.303 to        
                                               0.585                  
  Classification of BHR                  103   None or borderline     10%
                                               (PD~20~\> 4 mg)        
                                               Mild                   20%
                                               (PD~20~\> 1-4 mg)      
                                               Moderate to severe     70%
                                               (PD~20~≤ 1 mg)         
  Exhaled nitric oxide (ppb)             149   GM 11.04               
                                               95% CI 9.66 to 12.61   
  Atopic (SPT done in 164 subjects)            82%                    
  Sensitized to:                                                      
   Dust mite                                                          61%
   Cat                                                                49%
   Dog                                                                43%

BDP, beclomethasone dipropionate; SPT, skin prick testing.

Change in Lung Function, eNO, and BHR Over Time
-----------------------------------------------

The change in lung function, eNO, and BHR between 2 visits in the whole population and among sensitized and nonsensitized subjects are presented in Table [3](#T3){ref-type="table"}. In all subjects, FEV~1~(% predicted value) increased over time from 82.0 to 84.2% predicted \[95% CI for difference 0.2-4.1% predicted, *P*= 0.03\], although the absolute FEV~1~did not change. There was a 1.4-fold decrease in geometric mean (GM) eNO (95% CI for difference 1.2-1.6-fold, *P*\< 0.001), and no significant change in BHR.

###### 

Change in Spirometry, eNO, and BHR Between 2 Visits in the Whole Population and for Atopic and Nonatopic Subjects Only\*

                            FEV~1~(L)         FEV~1~(% Predicted)   FVC (L)           FVC (% Predicted)   eNO (ppb)     PD~20~(Doubling Doses)
  -------------- ---------- ----------------- --------------------- ----------------- ------------------- ------------- ------------------------
  All subjects   N          163               162                   137               137                 118           85
                 Mean       -0.00             2.27†                 0.02              2.33                -3.25†        0.29
                 (95% CI)   (-0.06 to 0.06)   (0.29-4.26)           (-0.07 to 0.12)   (-0.50 to 5.17)     (1.22-1.62)   (-0.13 to 0.72)
  Atopic         N          134               133                   110               110                 97            72
                 Mean       -0.00             2.72†                 0.04              3.30†               -3.93†        0.39
  Nonatopic      (95% CI)   (-0.06 to 0.05)   (0.54-4.90)           (-0.06 to 0.14)   (0.18-6.42)         (1.25-1.73)   (-0.04 to 0.83)
                 N          29                29                    27                27                  21            13
                 Mean       -0.00             0.21                  -0.06             -1.61               -1.10         -0.27
                 (95% CI)   (-0.18 to 0.17)   (-4.83 to 5.24)       (-0.32 to 0.21)   (-8.57 to 5.35)     (0.86-1.61)   (-1.84 to 1.30)

\*Lung function and BHR: mean changes (95% CI). eNO: geometric mean (95% CI for ratio).

†*P*\< 0.05 vs baseline.

Allergen Sensitization and Change in Lung Function, eNO, and BHR
----------------------------------------------------------------

Among atopic subjects, mean FEV~1~improved from 82.1 to 84.8% predicted (95% CI for difference 0.5-4.9% predicted, *P*= 0.015) and FVC from 96.2 to 99.5% predicted (95% CI for difference 0.2-6.4% predicted, *P*= 0.038), although the absolute FEV~1~and FVC did not change (Table [2](#T2){ref-type="table"}). ENO decreased 1.5-fold (95% CI for difference 1.2-1.7-fold, *P*\< 0.001). No such changes were observed in the nonatopic group.

Role of Allergen Exposure
-------------------------

Subjects were classified as being exposed to high levels of domestic allergens based on previously proposed criteria (\> 2 *μ*g/g Der p 1, \> 10 *μ*g/g Fel d 1, and \> 10 *μ*g/g Can f 1 in either carpet or mattress). Exposure to cat allergen was not associated with any changes in lung function, eNO, or BHR (Table [4](#T4){ref-type="table"}).

###### 

Change in Lung Function, eNO, and BHR Between 2 Visits According to Living Room Cat Allergen Exposure\*

  Fel d 1 (Living Room)              FEV~1~(L)         FEV~1~(% Predicted)   FVC (L)           FVC (% Predicted)   eNO (ppb)     PD~20~(Doubling Doses)   Between Group Doubling Dose Difference PD~20~(95% CI)
  ----------------------- ---------- ----------------- --------------------- ----------------- ------------------- ------------- ------------------------ -------------------------------------------------------
  Not exposed             N          115               114                   95                95                  81            60                       0.24
                          Mean       0.00              1.93                  0.03              2.18                -3.09†        0.33                     (-0.70 to 1.17)
                          (95% CI)   (-0.07 to 0.06)   (-0.48 to 4.35)       (-0.08 to 0.14)   (-1.26 to 5.62)     (1.14-1.68)   (-0.15 to 0.81)          
  Exposed                 N          49                49                    42                42                  38            26                       *t*test, *P*= 0.615
                          Mean       -0.03             2.68                  0.01              2.67                -3.58†        0.10                     ANOVA, *P*= 0.984
                          (95% CI)   (-0.15 to 0.09)   (-0.92 to 6.28)       (-0.17 to 0.19)   (-2.55 to 7.90)     (1.20-1.75)   (-0.82 to 1.02)          

\*Lung function and BHR: mean changes (95% CI). eNO: geometric mean (95% CI for ratio).

†*P*\< 0.05 vs baseline.

We found no difference in the change in lung function or eNO between subjects exposed or not exposed to the high level of dust mite allergen or dog allergen, although those not exposed to dog allergen did show an increase in FEV~1~over baseline of 2.4% predicted that was not seen in the dog-exposed group (Tables [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}). BHR improved among subjects who were not exposed to high Der p 1 levels from GM PD~20~= 359 *μ*g to GM PD~20~= 632 *μ*g; no such improvement was observed in the exposed group (GM PD~20~= 444 *μ*g at baseline vs GM PD~20~= 327 *μ*g at follow-up), and there was a 1.26 doubling dose (DD) difference in the change versus baseline comparing the nonexposed group to the exposed group (95% CI for difference 0.44-2.08 DD, *P*= 0.003). In the multivariate ANOVA model adjusting for the potential confounders (age, inhaled steroid use and dose, smoking status, baseline PD~20~, sensitization to house dust mite, and exposure to high levels of dog allergen), high exposure to dust mite allergen remained significantly and independently associated with the change in BHR \[estimated marginal means (95% CI): exposed -0.42 (-0.94 to 0.10) DD; nonexposed 0.86 (0.40-1.31) DD; *P*= 0.001 for difference; Table [5](#T5){ref-type="table"}\].

###### 

Change in Lung Function, eNO, and BHR Between 2 Visits According to Mattress Exposure to Dust Mite Allergen\*

  Der p 1 (Mattress)              FEV~1~(L)         FEV~1~(% Predicted)   FVC (L)           FVC (% Predicted)   eNO (ppb)     PD~20~(Doubling Doses)   Between Group Doubling Dose Difference PD~20~(95% CI)
  -------------------- ---------- ----------------- --------------------- ----------------- ------------------- ------------- ------------------------ -------------------------------------------------------
  Not exposed          N          84                84                    67                67                  58            48                       1.26
                       Mean       -0.03             1.77                  0.01              1.73                -2.89†        0.82†‡                   (0.44 to 2.08)
                       (95% CI)   (-0.12 to 0.05)   (-1.14 to 4.69)       (-0.13 to 0.15)   (-2.49 to 5.95)     (1.16-1.59)   (0.27-1.36)              
  Exposed              N          80                79                    70                70                  61            38                       *t*test, *P*= 0.003
                       Mean       0.01              2.57                  0.04              2.91                -3.60†        -0.44                    ANOVA, *P*= 0.001
                       (95% CI)   (-0.06 to 0.08)   (-0.17 to 5.31)       (-0.09 to 0.17)   (-1.00 to 6.82)     (1.14-1.85)   (-1.07 to 0.19)          

\*Lung function and BHR: mean changes (95% CI). eNO: geometric mean (95% CI for ratio).

†*P*\< 0.05 vs baseline; ‡*P*\< 0.05 vs exposed.

###### 

Change in Lung Function, eNO, and BHR Between 2 Visits According to Living Room Exposure to Dog Allergen\*

  Can f 1 (Living Room)              FEV~1~(L)         FEV~1~(% Predicted)   FVC (L)           FVC (% Predicted)   eNO (ppb)     PD~20~(Doubling Doses)   Between Group Doubling Dose Difference PD~20~(95% CI)
  ----------------------- ---------- ----------------- --------------------- ----------------- ------------------- ------------- ------------------------ -------------------------------------------------------
  Not exposed             N          125               124                   103               103                 84            72                       -1.00
                          Mean       0.01              2.43†                 0.04              2.51                -3.39†        0.10                     (-2.14 to 0.14)
                          (95% CI)   (-0.06 to 0.07)   (0.36-4.50)           (-0.07 to 0.14)   (-0.50 to 5.51)     (1.20-1.68)   (-0.39 to 0.58)          
  Exposed                 N          39                39                    34                34                  35            14                       *t*test, *P*= 0.085
                          Mean       -0.06             1.31                  -0.01             1.81                -2.92†        1.10†                    ANOVA, *P*= 0.019
                          (95% CI)   (-0.19 to 0.07)   (-3.93 to 6.55)       (-0.24 to 0.22)   (-5.44 to 9.06)     (1.03-1.85)   (0.33-1.86)              

\*Lung function and BHR: mean changes (95% CI). eNO: geometric mean (95% CI for ratio).

†*P*\< 0.05 vs baseline.

In subjects exposed to high Can f 1 level, BHR improved from GM PD~20~= 394 *μ*g to GM PD~20~= 843 *μ*g over a period of 4 years, or a mean 1.10 DD improvement (95% CI for difference 0.39-1.80 DD, *P*= 0.005). This improvement was not seen in the nonexposed group (baseline GM PD~20~= 394 *μ*g vs GM PD~20~= 422 *μ*g at 4 years). There was a 1.01 DD difference in change versus baseline comparing the exposed group to the nonexposed group (95% CI for difference -0.01 to 2.12 DD, *P*= 0.07). In the multivariate ANOVA model adjusting for the potential confounders (age, inhaled steroid use and dose, smoking status, exposure to house dust mite allergen, and baseline PD~20~), high exposure to dog allergen was significantly and independently associated with the improvement in BHR \[estimated marginal means (95% CI): exposed 1.17 (0.35-1.99) DD; nonexposed (-0.28 to 0.45) DD; *P*= 0. 019 for difference; Table [6](#T6){ref-type="table"}\].

To minimize the possibility that a change in dog ownership status may have confounded the results, the ANOVA model was repeated, first including \"lost a dog between visits 1 and 2\" as a confounder and second excluding from the analysis those subjects who had lost their dog. There was no change in the results in either case. For example, when subjects who got rid of their dog between visits 1 and 2 were excluded, there was again no change in BHR for those not exposed to high levels of dog allergen \[n = 70, mean (95% CI) 0.11 (-0.39 to 0.60) DD change\] but BHR decreased in those exposed to high Can f 1 levels \[n = 11, mean (95% CI) (0.20-1.99) DD change, *P*= 0.022\]. High dog allergen exposure was again significantly associated with the change in BHR in the multivariate ANOVA model (confounders: age, number of years with asthma, inhaled steroid use and dose, smoking status, dog sensitization, exposure to house dust mite allergen, and baseline PD~20~; *P*= 0.04).

For each allergen there was no significant effect of the interaction between exposure and sensitization in the multivariate models (data not shown). This was indirectly confirmed when we carried out the analysis according to the exposure and sensitization status (not sensitized/not exposed, not sensitized/exposed, sensitized/not exposed, and sensitized/exposed; Figure [1](#F1){ref-type="fig"}).

![**Mean (± 2 SE) PD~20~as doubling dose change from baseline by sensitization and exposure to mite (top) and dog (bottom)**. NS, not sensitized; NE, not exposed; S, sensitized; E, exposed.](1939-4551-2-5-83-1){#F1}

We then compared the actual allergen levels between individuals with \> 1 DD increase in PD~20~(deterioration), \> 1 DD decrease in PD~20~(improvement), and no change in BHR (the difference within 1 DD between 2 visits). Der p 1 decreased significantly, whereas Can f 1 increased significantly with the improving BHR (Figure [2](#F2){ref-type="fig"}). Subjects with \> 1 DD deterioration in PD~20~or more had 2.9-fold higher levels of Der p 1 detected in their mattress compared with those with no change or an improvement in PD~20~(95% CI for difference 0.87-9.31 *μ*g/g; multivariate ANOVA model, *P*= 0.046). For dog allergen, subjects with \> 1 DD improvement in PD~20~were exposed to 2.7-fold more dog allergen compared with those with no improvement or a deterioration in PD~20~(95% CI for difference 0.07-2.81 *μ*g/g; multivariate ANOVA model, *P*= 0.04).

![**Mean (± 2 SE) log allergen levels for mattress mite (top) and living room dog (bottom) categorized by doubling dose change in PD~20~**.](1939-4551-2-5-83-2){#F2}

Discussion
==========

Principal Findings
------------------

We have shown that exposure to high levels of dust mite allergen in persons with asthma was associated with a deterioration in BHR over a period of 4 years. The converse was true for dog allergen in that high exposure was associated with an improvement in BHR. These findings were in a large group of well-characterized persons with asthma and remained significant after potential confounders were introduced to the model. There was no independent effect of sensitization to the relevant allergen in this model.

Limitations
-----------

We are aware of the possible selection bias in our data set. Only a proportion of the original attendees were reviewed after 4 years, and those who agreed to attend for a second visit may not be representative of the whole cohort. Although we obtained domestic dust samples from more than 80% of these subjects, one of the primary end points (change in BHR) was measured at both visits in only 86 subjects. As we have acknowledged, these were not entirely typical of the group as a whole, in general, having milder disease requiring less treatment and with better lung function. This is in part because (for the reasons of safety) we did not carry out bronchial challenge in patients with marked airway obstruction (FEV~1~\< 60% predicted), and thus more severe asthma.

Another important potential confounder in our study is the high proportion of subjects who were taking inhaled steroids, at a reasonably high mean dose. This may well account for the mean improvements seen overall in eNO and FEV~1~percentage predicted over the study period. We included inhaled steroid use and dose as a covariate in the multivariate models where appropriate for this reason. We used a skin prick test wheal of minimum 3 mm greater than control to determine atopy. It is possible therefore that we underestimated sensitization, and future studies should include measurements of specific radioallergosorbent test IgE to minimize this possibility.

Regarding the unexpected findings with dog allergen exposure, there is a chance of type II error with only 14 subjects exposed. This may of course represent self-selection, with persons having more severe asthma avoiding dog exposure in the home, although there were no differences in other markers of asthma severity, such as PD~20~, eNO, FEV~1~, or inhaled corticosteroid dose at baseline between groups according to dog exposure (data not shown). It is also possible that domestic allergen exposure changed over the 4-year period, although a recent study has demonstrated acceptable stability over a similar period,\[[@B20]\] at least for mite and cat allergens.

Meaning of the Study
--------------------

That exposure to high levels of house dust mite allergen was associated with deteriorating BHR was not an unexpected finding. House dust mite allergens include a number of proteases and trypsins that may disrupt cell membranes and have direct pro-inflammatory actions, and they also mediate airway inflammation through IgE activation \[[@B21]\]. They may therefore contribute to the persistence of airway inflammation over time, and perhaps a consequent increase in bronchial hyperresponsiveness.

Early-life exposure to dogs is associated with a reduced likelihood of developing asthma in children,\[[@B22]\] but there are no data for adults with asthma. It is interesting therefore that we have found an association between exposure to high levels of dog allergen and improvement of BHR. We considered the possibility that subjects may have gotten rid of their dog between visits, but even after controlling for this, we discovered that the association remained the same. It is also possible that dog ownership per se conferred the observed improvements. However, when we tested for an association between dog ownership and change in BHR, we found none (data not shown). One other possibility is that tolerance resulting from high dog allergen exposure may have developed in the skin prick negative subjects and could be responsible for some of the difference seen. Although there was no correlation between levels of dust mite and dog allergens (data not shown), it is still possible of course that there are other important confounding variables that we have not measured, such as domestic levels of endotoxin or fungal spores. The relationship between exposure to endotoxin or mold and asthma is unclear. Some studies have shown an inverse association with allergic sensitization and asthma in children,\[[@B23],[@B24]\] but others demonstrated increased risk for asthma prevalence \[[@B25]\].

The majority of our subjects were atopic, and this group as a whole improved over time in terms of lung function and eNO, whereas the nonatopic group did not. Dijkstra and colleagues followed 122 persons with asthma for more than 23 years and reported no association between atopy and lung function change \[[@B26]\]. However, atopy was more common (98% vs 87%) in the 159 subjects excluded from the analysis, either because they had never used inhaled corticosteroids or had insufficient longitudinal data. It is likely, therefore, that this group had less severe asthma. Another longitudinal study reported a lower prevalence of irreversible airflow obstruction in persons with atopic asthma \[[@B6]\]. It is likely that different, although not necessarily independent, factors are important when considering asthma development, asthma severity, and asthma progression. It is also likely that these factors may differ between recognized asthma phenotypes, such as late onset versus early onset or atopic versus nonatopic.

Conclusions
===========

We have demonstrated that exposure to high levels of house dust mite allergen in the home, over a period of 4 years, is associated with deteriorating bronchial hyperresponsiveness, whereas the converse is true for dog allergen exposure. If these findings are confirmed over longer periods of time, further investigation into the favorable association between dog allergen exposure and prognosis will be required, and possibly targeted intervention in those exposed to high levels of house dust mite allergen, irrespective of their sensitization status.
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